首页> 外文期刊>Clinical oncology >Radiation therapy for cervix carcinoma: benefits of individualized dosimetry.
【24h】

Radiation therapy for cervix carcinoma: benefits of individualized dosimetry.

机译:宫颈癌放射治疗:个体化剂量学的好处。

获取原文
获取原文并翻译 | 示例
       

摘要

This study is a presentation of the prospective collection of data on patients treated by radical radiotherapy at Westmead Hospital between December 1989 and December 1998. The impact of the routine use of individualized dosimetry and lower brachytherapy dose on patients was examined, by comparing the historical series of patients treated between 1989 to 1991 to the later patients treated with inividualised dosimetry. There were 163 patients treated with external beam and intracavitary radiotherapy during this period. Histology was squamous carcinoma in 80% (132 patients), adenocarcinoma in 13% (22 patients), and adenosquamous carcinoma in 6% (9 patients). Patients were generally treated with 50 Gy in 25 fractions to the pelvis followed by 1 low dose rate caesium intracavitary brachytherapy insertion. Patients who had dosimetry generally received 20 Gy to point A via the insertion compared to 30 Gy in the non-dosimetry group. Median follow-up was 62 months. Only 22% (18) of patients failed with disease outside the pelvis. Pelvic control was similar in the patients who had dosimetry as opposed to no dosimetry (P=0.8). In the dosimetry group there were less grade III or higher bowel toxicity (P=0.01) and less vaginal fistulae (P=0.03). The actuarial two-year survival was 56.2% in the no dosimetry group and 68.6% in the dosimetry group. When controlled for stage and performance status patients who had dosimetry had a statistically significant greater overall survival (P=0.02). Thus we found that the routine use of dosimetry was associated with a lower brachytherapy dose, decreased complications, without any decrease in local control or survival.
机译:这项研究是对1989年12月至1998年12月在Westmead医院接受根治性放射治疗的患者的数据的前瞻性收集。通过比较历史系列资料,研究了常规使用个体化剂量法和较低的近距离放射治疗剂量对患者的影响在1989年至1991年之间接受治疗的患者中,有60%的患者后来接受了单独剂量学治疗的患者。在此期间,有163例患者接受了外部束和腔内放疗。组织学为80%(132例)为鳞癌,13%(22例)为腺癌,6%(9例)为腺鳞癌。患者通常在骨盆部25个部位接受50 Gy剂量治疗,然后进行1次低剂量率的铯腔内近距离放射治疗。进行剂量测定的患者通常通过插入接受20 Gy到A点,而非剂量测定组为30 Gy。中位随访时间为62个月。只有22%(18)的患者因骨盆外疾病失败。有剂量测定的患者的骨盆控制与没有剂量测定的患者相似(P = 0.8)。在剂量测定组中,III级或更高的肠毒性(P = 0.01)和阴道瘘少(P = 0.03)。无剂量测定组的精算两年生存率为56.2%,剂量测定组为68.6%。当控制阶段和表现状态时,具有剂量测定法的患者的总体生存率具有统计学显着性(P = 0.02)。因此,我们发现剂量测定法的常规使用与较低的近距离放射治疗剂量,减少的并发症以及局部控制或生存率没有任何降低有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号